Explore /
Poster
/ Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

Authors

James R. Berenson

Institute for Myeloma and Bone Cancer Research, West Hollywood, CA

James R. Berenson , James D. Hilger , Robert Dichmann , Dipti Patel-Donnelly , Ralph V. Boccia , Alberto Bessudo , Laura Stampleman , Donald Gravenor , Shahrooz Eshaghian , Hilda Chamras , Youram Nassir , Regina A. Swift , Robert A. Vescio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT01365559

Citation

J Clin Oncol 31, 2013 (suppl; abstr 8599)

DOI

10.1200/jco.2013.31.15_suppl.8599

Abstract #

8599

Poster Bd #

55D

Abstract Disclosures

Similar Posters

Poster

2013 ASCO Annual Meeting

$A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).$